Lilly’s Migraine Drug Emgality Fails to Outperform Pfizer’s Nurtec

Eli Lilly's Emgality drug failed to demonstrate statistical superiority over Pfizer's Nurtec in the CHALLENGE-MIG trial. The proportion of patients experiencing a 50% reduction in migraine headache days per month was statistically similar between the two drugs, although Emgality did achieve clinically meaningful efficacy and safety outcomes compared to a placebo. The CHALLENGE-MIG study is the f..